Browsing Tag
IgA nephropathy
14 posts
Will multi-year kidney function data secure Vanrafia’s long-term positioning?
Novartis Pharma AG’s ALIGN data test whether eGFR slope preservation can confirm Vanrafia’s clinical benefit. Read the full executive analysis.
Biohaven (NYSE: BHVN) deprioritizes BHV-7000 in depression after Phase 2 miss, shifts focus to epilepsy, obesity, and immunology
Biohaven ends BHV-7000 depression trials after Phase 2 miss. Find out why it's shifting R&D focus to epilepsy, obesity, and immunology in 2026.
Can povetacicept reshape autoimmune kidney care? Vertex Pharmaceuticals’ RUBY-3 trial shows promise
Vertex’s RUBY-3 trial shows strong 48-week data for povetacicept in IgAN and pMN. Find out how this sets the stage for late-stage trials and regulatory filings.
Telitacicept delivers breakthrough proteinuria decline in Chinese IgA nephropathy phase 3 study
Find out how RemeGen’s Telitacicept achieved phase 3 success in reducing proteinuria for IgA nephropathy patients in China.
Travere Therapeutics stock soars 25% as FDA skips advisory panel for FSGS drug FILSPARI
Travere stock jumped 25% after the FDA waived an advisory panel for its FSGS drug. Find out why FILSPARI could transform the rare kidney disease market.
BioCity’s SC0062 secures second breakthrough therapy designation in China for diabetic kidney disease
BioCity Biopharma’s ETA-selective SC0062 earns second Breakthrough Therapy Designation in China for diabetic kidney disease, reinforcing its CKD potential.
FILSPARI secures full European approval: A major breakthrough for IgA nephropathy patients
Find out how FILSPARI’s full EU approval marks a major step for IgA nephropathy treatment and strengthens CSL Vifor and Travere Therapeutics’ rare disease focus.
Triastek’s 3D-printed D23 tablet shows strong clinical results for IgAN treatment
Triastek has reported promising clinical results for its 3D-printed drug delivery product, D23 (Budesonide Ileum Targeted Tablets), which…
Primary IgA nephropathy : FDA grants full approval to Travere Therapeutics’ Filspari
In a groundbreaking move, the US Food and Drug Administration (FDA) has granted full approval to Travere Therapeutics’…
Novartis’ atrasentan shows significant reduction in proteinuria in seasonal allergic rhinitis patients
Novartis presented compelling interim results from the Phase III ALIGN study evaluating the efficacy of atrasentan, an investigational…